<DOC>
	<DOCNO>NCT02215135</DOCNO>
	<brief_summary>Corifollitropin alfa , single dose administer sustains multiple follicular development 7 day . However , It may induce ovarian hyperstimulation syndrome ( OHSS ) , especially high responder woman patient polycystic ovary syndrome ( PCOS ) . In GnRH antagonist protocol agonist trigger final oocyte maturation , follow embryo cryopreservation almost eliminate risk OHSS . To decrease injection burden prevent OHSS PCOS patient undergo IVF treatment , ovarian hyperstimulation Corifollitropin alfa GnRH antagonist protocol GnRH agonist trigger final oocyte maturation , follow elective embryo cryopreservation design study . The purpose trial conduct confirm whether novel protocol could prevent OHSS , decrease injection burden PCOS patient single dose corifollitropin alfa could support multiple follicular growth 7 day .</brief_summary>
	<brief_title>Corifollitropin Alfa Application PCOS Patients</brief_title>
	<detailed_description>BACKGROUNG : Ovarian hyperstimulation syndrome ( OHSS ) serious complication ovulation induction . Therefore , Corifollitropin alfa , long act recombinant follicular stimulation hormone ( rFSH ) application PCOS woman warn . However , corifollitropin alfa could decrease injection burden patient undergo IVF/ICSI treatment . In previous study , embryo cryopreservation follow GnRH agonist trigger final oocyte maturation GnRH antagonist protocol almost eliminate risk OHSS . This study design analyze whether ovarian hyperstimulation PCOS woman Corifollitropin alfa GnRH antagonist protocol GnRH agonist trigger , follow freeze embryos decrease injection burden without OHSS complication . PURPOSE : To assess whether single dose Corifollitropin alfa sustain multiple follicular growth seven day GnRH antagonist protocol application PCOS woman , follow embryo cryopreservation GnRH agonist trigger decrease injection benefit without OHSS complication . METHODS : This prospective , single center , observational study , thirty fifty PCOS woman age 20-38 year old , In GnRH antagonist protocol , single dose corifollitropin alfa administer ovarian stimulation ( S1 , stimulation D1 ) . Seven day later , rFSH daily inject stimulate follicle development accord ovarian response . GnRH antagonist administer daily S5 day final oocyte maturation . GnRH agonist give replace hCG trigger final oocyte maturation three follicle reach 17 mm size . The IVF ICSI plan embryos elective cryopreservation . Transfer embryo perform subsequent frozen-thawed ET cycle . Primary outcome measure incidence OHSS . The secondary outcome measure number oocyte retrieval , number embryos frozen pregnancy rate subsequent FET cycle . ANTICIPATED RESULTS : Decreasing injection burden maximal oocytes retrieve without severe OHSS complication .</detailed_description>
	<mesh_term>Deslorelin</mesh_term>
	<criteria>The diagnosis PCOS accord Rotterdam criterion ( twoi three ) include : chronic anovulation manifest symptom oligomenorrhoea ultrasonographic evidence polycystic enlarge ovary 10 peripherally locate follicle 38mm diameter around dense central stroma hyperandrogenaemia ( serum testosterone concentration 0.8 ng/ml ) clinical hyperandrogenism . A diagnosis congenital adrenal hyperplasia , Cushing 's syndrome , androgenproducing tumour , hyperprolactinaemia thyroid dysfunction exclude . patient older 38 year serum FSH level 12 mIU/ml . patient wiht previous ovarian surgery husband nonobstructive azoospermia</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>38 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Corifollitropin alfa</keyword>
	<keyword>polycystic ovarian syndrome ( PCOS )</keyword>
	<keyword>control ovarian hyperstimulation ( COS )</keyword>
	<keyword>GnRH antagonist protocol</keyword>
	<keyword>Ovarian hyperstimulation syndrome ( OHSS )</keyword>
</DOC>